Influence of Synovial Fluid Biochemical Markers on Clinical Outcomes Following Arthroscopic and Non-Arthroscopic Patients with Knee Osteoarthritis
Authors:
Open Access
- 13 March 2026
- journal article
- Published by Open Medical Publishing in Orthopedic Reviews
- Vol. 18, 158292
Abstract
Background: Osteoarthritis (OA) is a degenerative joint disorder that causes pain, stiffness, and functional impairment. Conventional treatments relieve symptoms but do not restore cartilage, limiting long-term efficacy. Cell-based therapies, including mesenchymal stem cells (MSCs) and MSC-derived secretome, have emerged as promising strategies for cartilage regeneration. Object: This study aimed to assess the therapeutic effects of UC-MSCs and UC-MSC-derived secretome in OA patients through both clinical outcomes and synovial fluid (SF) analyses. Methods: Eligible participants were divided into two groups; group who underwent arthroscopy and group who did not. All the participants received an intra-articular injection consisting of an initial 2 mL dose of UC-MSC secretome, followed by 10 million UC-MSCs, and two additional 2 mL doses of secretome administered biweekly. Synovial fluid samples were collected at baseline and 12 weeks post-treatment, centrifuged to obtain the supernatant, and analyzed for inflammatory cytokines and matrix-degrading markers using multiplex and ELISA assays. Clinical evaluations were conducted at 6- and 12-months post-treatment. Result: The results showed that UC-MSC therapy significantly improved functional outcomes in patients with knee osteoarthritis, as indicated by WOMAC scores up to six months. In vitro studies showed similar results, where co-culture of osteoarthritic synovial fluid-derived MSCs with UC-MSCs or UC-MSC secretome enhanced proliferation and differentiation while rapidly reducing pro-inflammatory cytokines (IL-1β, IFN-γ, IL-6, IL-12p70, IL-17A, IL-18) and MMPs (MMP1, MMP7, MMP13). Conclusion: Our findings support a two-stage therapeutic strategy in which UC-MSC secretome first alleviates inflammation, followed by UC-MSCs to promote cartilage regeneration. Post-injection rehabilitation or repeated MSC dosing may further enhance treatment efficacy, highlighting the potential of MSC-based therapies for knee OA management.Keywords
This publication has 29 references indexed in Scilit:
- The role of inflammatory mediators and matrix metalloproteinases (MMPs) in the progression of osteoarthritisBiomaterials and Biosystems, 2024
- Diagnosis and Treatment of Hip and Knee OsteoarthritisJAMA, 2021
- Regenerative Potential of Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis and Chondral Defects: A Systematic Review and Meta‐analysisArthroscopy, 2020
- Osteoarthritis and stem cell therapy in humans: a systematic reviewOsteoarthritis and Cartilage, 2018
- Regenerative approaches for cartilage repair in the treatment of osteoarthritisOsteoarthritis and Cartilage, 2017
- Knee osteoarthritis has doubled in prevalence since the mid-20th centuryProceedings of the National Academy of Sciences, 2017
- MSC exosome as a cell-free MSC therapy for cartilage regeneration: Implications for osteoarthritis treatmentSeminars in Cell & Developmental Biology, 2017
- Overexpression of HMGB1 A-box reduced IL-1β-induced MMP expression and the production of inflammatory mediators in human chondrocytesExperimental Cell Research, 2016
- The effect of pro-inflammatory cytokines on immunophenotype, differentiation capacity and immunomodulatory functions of human mesenchymal stem cellsCytokine, 2016
- New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: Outside-in signaling and relationship to tumor progressionBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2012